Quest Diagnostics Moves to Convenient Nonfasting Cholesterol Testing with Improved Method for Assessing Heart Disease Risk and Aiding Treatment Decisions

Quest Diagnostics Moves to Convenient Nonfasting Cholesterol Testing with Improved Method for Assessing Heart Disease Risk and Aiding Treatment Decisions

Quest – SECAUCUS, N.J.Sept. 7, 2017 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that all of the company’s cholesterol test services that involve estimates of low-density lipoprotein cholesterol (LDL-C) now use a novel calculation shown to improve the accuracy of testing for levels of LDL-C, a key marker of risk of cardiovascular disease. (Read More)

Leave a Reply